Clinical practice — labs, cases, documentation

The premise

The previous seven modules established the science. This one turns it into a working clinic. A defensible Nimbus BHRT practice rests on six operational pillars: ordering the right comprehensive panel, interpreting the result against optimal (not "normal") ranges with vendor-aware conversion, timing the patient's medication and labs so the result is interpretable, routing the compounded prescription to a vetted pharmacy partner, executing the consent and documentation discipline that protects against board complaints, and running a business model that supports a cash-pay plus insurance hybrid workflow.

Two themes run through every section. The first is audit defensibility — every recommendation in a Nimbus chart must include (a) an objective lab rationale, (b) a symptom rationale, and (c) a patient-stated goal, so that a hostile reviewer cannot reconstruct the plan as a marketing exercise. The second is interpretive humility — the lab vendor, the draw timing, the patient's last cream application, and the assay choice can each move a hormone value by a clinically meaningful amount. A result without context is a guess.

Anchor — the lab-timing trap

Comprehensive panels — initial postmenopausal female workup

The Nimbus baseline panel for a postmenopausal woman initiating HRT is broader than the typical "menopause workup" and includes the metabolic, nutritional, and HPG-axis analytes that gate decisions across the seven modality modules. Every analyte on this list serves a specific downstream decision.

• CBC with differential and platelet count — baseline for hematocrit monitoring on testosterone if added later.
• CMP and lipid panel — liver function gates oral estradiol and oral USP testosterone; lipid trends are a primary outcome variable on oral E2.
• DHEA-sulfate — baseline for the DHEA module decision (target 200–250 mcg/dL in women).
• Estradiol (LC/MS/MS preferred for the low postmenopausal range) — the primary estrogen-titration analyte against the Nimbus 75–100 pg/mL target.
• Free T3 / Free T4 / TSH — the thyroid trio; symptoms plus Free T3 drive the thyroid decision per module 05.
• FSH — confirms menopausal status; not used for titration.
• Hemoglobin A1c and insulin — metabolic baseline; insulin resistance is one of the features that pushes a patient toward oral E2 (lipid benefit) and toward DHEA replacement.
• LH — paired with FSH for menopausal-status confirmation and for differentiating ovarian from pituitary causes of anovulation in perimenopausal women.
• Progesterone — vendor matters; Quest target ≥10 ng/mL, LabCorp/Access target ≥3 ng/mL (×3.5 ≈ Quest scale).
• Testosterone Free and Total — baseline for the T-in-women module (targets total 200–300 ng/dL; Free 3–4 pg/mL LabCorp / 6–8 pg/mL Quest).
• Vitamin B12 and Vitamin D-25 Hydroxy — nutritional gates that confound symptom interpretation when low.

TODO(citation): Confirm the Nimbus default whether TPO antibodies belong in the baseline panel. Internal policy currently treats TPO as optional (does not change treatment when Free T3 + symptoms drive the plan) — see IntelliHealth_V6_BHRT_Gap_Analysis.md §1. Medical-director sign-off pending.

Comprehensive panels — initial male workup

The male baseline panel drops the female-specific HPG analytes (FSH/LH/E2/P4 are not routine in men outside specific work-ups), drops insulin (covered by A1c for the general metabolic gate), and adds PSA Free and Total for the prostate-safety baseline that gates testosterone replacement per module 04.

• CBC with differential and platelet count — baseline hematocrit; recheck on TRT to catch the Hct ≥52% → reduce, Hct ≥54% → hold thresholds.
• CMP and lipid panel — liver function and lipid baseline.
• DHEA-sulfate — male target 500–600 mcg/dL.
• Free T3 / Free T4 / TSH — thyroid trio.
• Hemoglobin A1c — metabolic baseline.
• PSA Free and Total — prostate baseline at age ≥40 with risk factors or ≥55 generally; see the PSA decision tree below for the percent-free PSA reflex rule when total >2.5 ng/mL.
• Testosterone Free and Total — primary T-titration analytes against the Nimbus targets (Total 200–300 ng/dL; Free 170–210 pg/mL Quest or 30–40 pg/mL LabCorp).
• Vitamin B12 and Vitamin D-25 Hydroxy — nutritional gates.

For low-T men with prolactin >40 ng/mL, defer TRT pending pituitary work-up — this is a hard gate covered in module 04 and revisited under safety blocks below.

Comprehensive panels — followup cadence

Initial recheck at 8–12 weeks, then 3–6 months for stable patients, then annual minimum thereafter. The recheck is targeted, not full panel — re-test only the analytes being titrated plus the safety-monitoring analytes for that modality.

• Estradiol titration → re-test E2, recheck lipid panel and liver enzymes at 6–12 months.
• Progesterone titration or new bleeding → re-test P4 with vendor-aware conversion; TVUS endometrial-stripe assessment per module 02 decision tree.
• Testosterone titration (men) → re-test Total T, Free T, Hct, PSA, plus estradiol when high-dose or aromatization concerns.
• Testosterone (women) → re-test Total + Free T; symptom-driven dose adjustment.
• Thyroid titration → re-test TSH, Free T3, Free T4; symptoms drive the decision more than the TSH number.
• DHEA titration → re-test DHEA-S only; aim for sex-specific optimal target.

Lab-draw timing — the rules that protect against artifact

Drawing the right analyte at the wrong time produces an interpretable-looking number that points the clinician in the wrong direction. The Nimbus timing matrix is short, deterministic, and patient-explainable.

Men.

• Cream: apply the night before AND the morning of the draw; test 4 hours after the AM application.
• Injectable cypionate or enanthate: decide peak vs. trough in advance; mid-interval is the typical Nimbus default for routine titration.
• Thyroid: take the dose first thing AM on an empty stomach, 30 minutes before food or supplements; test 4 hours later.
• DHEA: take the morning dose; test 4 hours later (paired with the thyroid draw).
• PSA prep: 3 days without vigorous exercise, cycling, sexual activity, or DRE before draw.

Women.

• The night before labs: take evening doses of progesterone and testosterone.
• The morning of labs: thyroid first (30 minutes before other meds), then DHEA and oral estradiol if postmenopausal.
• Draw window: 4–5 hours after the morning medications.

Holds.

• Hold combined OCP, ring, Depo, or etonogestrel implant for 1 month before any HPG-axis labs — these suppress FSH/LH and block progesterone receptors, producing artifactually low gonadotropins and an uninterpretable hormone panel.

The timing matrix is one of the most common sources of artifactual "treatment failure" in referrals into Nimbus from outside clinics — a patient on a transdermal patch drawn at trough, a man on T cream drawn before his morning application, or a postmenopausal woman whose morning progesterone was drawn before she took her evening dose. Before escalating a dose, ask whether the result is interpretable.

Lab vendors and assay precision

Nimbus interfaces with four primary cash-pay vendors plus standard insurance billing through Quest and LabCorp. The choice between them is driven by (a) which assay precision is needed, (b) which insurance the patient carries, and (c) which analyte is being measured.

• Evexia Diagnostics — broad cash-pay catalog negotiated through the Resource Hub; preferred for full comprehensive panels at low cash-pay cost.
• Access Labs — cash-pay LabCorp draw; LabCorp-scale results, so the ×3.5 progesterone conversion applies relative to Quest-scale targets.
• Quest Diagnostics — direct cash-pay through Quest portal; preferred when the patient has prior Quest results to trend against (vendor consistency matters more than absolute vendor for individual-patient trending).
• Rupa Health — aggregator that brokers multiple specialty assays; useful for LC/MS/MS estradiol or specialty thyroid sub-fractionation when the standard panel is insufficient.

Assay precision. For low postmenopausal estradiol (target 75–100 pg/mL), prefer LC/MS/MS (liquid chromatography with tandem mass spectrometry) over immunoassay. At the low end of the range, immunoassay precision degrades and can produce a ~30 pg/mL swing on the same blood draw run twice. The patient who looks under-dosed on immunoassay may be at target on LC/MS/MS.

TODO(citation): Confirm the Nimbus-preferred specific LC/MS/MS reference lab and the negotiated cash-pay code through the Resource Hub. Currently policy-only.

Saliva testing — the Nimbus position

The clinical risk is asymmetric. False reassurance from a salivary progesterone in a woman on systemic estradiol leaves the endometrium and breast at risk while the chart records a defensible-looking "protective range" result. Serum P4 with the Quest target ≥10 ng/mL (or LabCorp ≥3 ng/mL, equivalent to ~10.5 ng/mL on the Quest scale via the ×3.5 conversion) is the only Nimbus-defensible measurement for endometrial-protection adequacy.

Cross-vendor conversions — the ×3.5 progesterone factor and Free T vendor differences

Quest and LabCorp do not measure the same analyte the same way. For progesterone in particular, LabCorp and Access measure only progesterone itself, while Quest captures progesterone plus key metabolites. The empirical conversion factor is ×3.5: a LabCorp progesterone of 3 ng/mL corresponds to roughly 10.5 ng/mL on the Quest scale, which is at the Nimbus ≥10 ng/mL postmenopausal-on-treatment target.

Free testosterone behaves differently across vendors as well — LabCorp Free T runs roughly six-fold lower than Quest Free T for the same patient, so the optimal-range thresholds are vendor-specific:

• Free T in women: 3–4 pg/mL LabCorp / 6–8 pg/mL Quest.
• Free T in men: 30–40 pg/mL LabCorp / 170–210 pg/mL Quest.

Document which vendor produced the result you are interpreting on every chart note. The single most common preventable error in BHRT chart review is interpreting a LabCorp result against a Quest target or vice versa.

PSA workup integration

The PSA decision tree from module 04 lives here in operational form. The reflex rule: percent-free PSA is ordered when total PSA exceeds 2.5 ng/mL, the urology-referral thresholds are deterministic, and the suspected-prostatitis workflow includes an empiric antibiotic course before re-checking.

The clinical pearl that operationalizes the tree: total PSA 2.5–4.0 ng/mL with percent-free above 20% is benign-flavored and gets a 3-month recheck; below 10% is cancer-flavored and gets a same-cycle urology referral; the 10–20% band is the gray zone where suspected prostatitis gets a TMP-SMX 800/160 PO q12h × 14 days empiric trial with PSA re-checked 3–4 months after completion. The 5-alpha-reductase inhibitor and statin caveats on PSA-lowering (~50% reduction with 5-ARIs, smaller signal with statins, NSAIDs, acetaminophen, thiazides) live in the chart note alongside the PSA value, not in the prescriber's memory.

Thyroid titration in practice

Module 05 established the framework — symptoms drive the decision, Free T3 is the primary analyte, the optimal 4.0–4.3 pg/mL Free T3 target sits well inside lab "normal." The DTE titration widget consolidates the practical dose ladder from baseline through the typical 60–120 mg/day Nimbus range with the lab and symptom checkpoints at each step.

The two documentation rules attached to thyroid prescribing are non-negotiable. The indication must never be weight loss (FDA Boxed Warning on all thyroid hormones; route weight-management requests to the GLP-1 / WeightWise tier). DTE prescriptions are off-label when titrated to Free T3 and symptoms beyond labeled hypothyroidism criteria — the off-label tag belongs in the SOAP plan with a symptom-suggestive rationale.

Mammogram and DEXA cadence on HRT

Two surveillance studies anchor a postmenopausal woman's annual visit on HRT. The Nimbus defaults below are policy candidates pending medical-director sign-off but reflect current practice.

• Annual mammogram while on HRT. The mainstream comparator is biennial screening for average-risk women aged 50–74 per ACOG and USPSTF current guidance; the Nimbus default narrows this to annual on the rationale that HRT introduces a non-zero modifier on breast-tissue surveillance that warrants the tighter cadence.
• DEXA every 1–2 years with the expectation of improvement on hormones. The mainstream USPSTF comparator recommends initial DEXA at age 65 for average-risk women, with rescreening intervals based on T-score. On HRT, case-level data demonstrate a measurable trajectory of improvement (e.g., T −1.9 → −1.4 over 5 years of optimization), and the cadence is set to capture that trajectory rather than to wait for fracture.

TODO(citation): Confirm specific ACOG mammogram cadence guidance PubMed identifier and USPSTF DEXA screening guidance citation for the comparator footnotes. Internal dossier flags both as policy candidates pending medical-director sign-off; see IntelliHealth_V6_BHRT_Gap_Analysis.md §1 and §2.10.

Documentation discipline — the SOAP-plan checklist

Every initial visit and every initiation Rx must produce a SOAP-plan entry that survives board-complaint review. The checklist below is the minimum.

• Indication: symptom-suggestive language when the patient is symptomatic-only ("fatigue, hair thinning, low libido consistent with optimization candidate"), or the specific lab-and-symptom combination when both are present.
• Off-label tag where applicable — compounded preparations, off-label DTE titration to Free T3, female testosterone, off-label DHEA above target, off-label vaginal estradiol for rUTI prevention, etc. The off-label label is not a warning; it is a documentation trigger.
• Risk/benefit discussion bullet — one sentence summarizing the conversation, not the full consent document.
• Patient-acknowledgment statement — "Patient acknowledges understanding of the above" language, preferably with the patient-stated goal recorded in their own words.
• Consent version reference — "Consents reviewed per Nimbus BHRT consent v[X]" — flag any chart that lacks this string.

Two branding constraints carry forward from the gap analysis.

The "board-complaint resilience" frame: every recommendation must include an objective lab rationale, a symptom rationale, and a patient-stated goal. A chart with all three is defensible. A chart with only one is not.

A walk-through case — putting it together

Patient A, 56 yo female. Presents for HRT consultation with ~14 months since final menstrual period. Chief complaints: nightly hot flashes interrupting sleep, persistent daytime fatigue despite ~8 hours in bed, mild cognitive complaints ("can't find the right word"), and decreased libido. Past medical history significant for mild hypertriglyceridemia controlled with diet; BMI 27; non-smoker; no personal or family history of VTE or breast cancer; intact uterus; last mammogram normal 4 months prior.

Workup. Order the postmenopausal female comprehensive panel above. Counsel the patient to take her evening doses the night before labs (none yet at baseline), thyroid first thing AM 30 min before food, then draw 4–5 hours later. She is not on an OCP, so no hold required.

Results (illustrative). Estradiol 12 pg/mL (LC/MS/MS), FSH 78, LH 42, progesterone Quest 0.5 ng/mL, Free T3 3.1 pg/mL (low optimal), TSH 2.8 (high-end normal, low-optimal), Free T 2.1 pg/mL Quest (below 6–8 optimal), Total T 18 ng/dL (below 200–300 optimal), DHEA-S 95 mcg/dL (below 200–250 optimal), A1c 5.4%, B12 normal, Vit D 28 ng/mL (insufficient).

Plan. Given BMI 27 and mild hypertriglyceridemia, route choice is a judgment call — the hypertriglyceridemia is one of the seven transdermal-trigger factors, but its severity is mild. The Nimbus-defensible plan documents the route rationale either way. Initiation plan (one option):

• Estradiol: transdermal patch 0.05 mg/day (transdermal selected on the hypertriglyceridemia trigger). Target serum E2 75–100 pg/mL mid-interval.
• Progesterone: oral micronized P4 200 mg QHS for endometrial protection. Off-label tag for compounded routes if used.
• Testosterone: topical T cream titrated against symptoms and Free T toward 6–8 pg/mL Quest; off-label in women.
• Thyroid: symptom-driven; consider DTE titration per module 05 with Free T3 target 4.0–4.3 pg/mL. Off-label tag.
• DHEA: 25 mg PO QAM toward female target 200–250 mcg/dL.
• Vitamin D: repletion to optimal 50–80 ng/mL per general internal-medicine practice.
• Surveillance: annual mammogram (per Nimbus policy candidate); DEXA at baseline and every 1–2 years; recheck labs at 8–12 weeks.

SOAP-plan documentation. Indication is symptom-suggestive (vasomotor symptoms, sleep disruption, cognitive complaints, libido). Off-label tags applied to compounded preparations, female T, and DTE titration. Risk/benefit discussion documented. Patient-acknowledgment statement recorded with her stated goal in her own words. Consent reviewed per Nimbus BHRT consent.

No antiaging language anywhere in the chart. No weight-loss indication on the thyroid order. The plan survives board-complaint review because every recommendation has objective lab rationale, symptom rationale, and patient-stated goal.

Mid-module checkpoint — lab-draw timing

Role-specific applied content

High-yield facts

Post-test — synthesis

Module evaluation